Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice

Calderon-Goercke, M; Castaneda, S; Aldasoro, V; Villa, I; Prieto-Pena, D; Atienza-Mateo, B; Patino, E; Moriano, C; Romero-Yuste, S; Narvaez, J; Gomez-Arango, C; Perez-Pampin, E; Melero, R; Becerra-Fernandez, E; Revenga, M; Alvarez-Rivas, N; Galisteo, C; Sivera, F; Olive-Marques, A; del Buergo, MA; Marena-Rojas, L; Fernandez-Lopez, C; Navarro, F; Raya, E; Galindez-Agirregoikoa, E; Arca, B; Solans-Laque, R; Conesa, A; Hidalgo, C; Vazquez, C; Roman-Ivorra, JA; Loricera, J; Lluch, P; Manrique-Arija, S; Vela, P; De Miguel, E; Torres-Martin, C; Nieto, JC; Ordas-Calvo, C; Salgado-Perez, E; Luna-Gomez, C; de Miera, FJTS; Fernandez-Llanio, N; Garcia, A; Larena, C; Gonzalez-Vela, C; Corrales, A; Varela-Garcia, M; Aurrecoechea, E; Dos Santos, R; Garcia-Manzanares, A; Ortego, N; Fernandez, S; Ortiz-Sanjuan, F; Corteguera, M; Hernandez, JL; Gonzalez-Gay, MA; Blanco, R – 2020